| Drug resistance in leishmaniasis SL Croft, S Sundar, AH Fairlamb Clinical microbiology reviews 19 (1), 111-126, 2006 | 2106 | 2006 |
| Antimalarial drug discovery: efficacy models for compound screening DA Fidock, PJ Rosenthal, SL Croft, R Brun, S Nwaka Nature reviews Drug discovery 3 (6), 509-520, 2004 | 1217 | 2004 |
| Leishmaniasis–current chemotherapy and recent advances in the search for novel drugs SL Croft, GH Coombs Trends in parasitology 19 (11), 502-508, 2003 | 1137 | 2003 |
| Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda PJ Guerin, P Olliaro, S Sundar, M Boelaert, SL Croft, P Desjeux, ... The Lancet infectious diseases 2 (8), 494-501, 2002 | 1047 | 2002 |
| Kinetoplastids: related protozoan pathogens, different diseases K Stuart, R Brun, S Croft, A Fairlamb, RE Gürtler, J McKerrow, S Reed, ... The Journal of clinical investigation 118 (4), 1301-1310, 2008 | 727 | 2008 |
| Current scenario of drug development for leishmaniasis. SL Croft, K Seifert, V Yardley The Indian journal of medical research 123 (3), 399-410, 2006 | 538 | 2006 |
| Chemotherapy of trypanosomiases and leishmaniasis SL Croft, MP Barrett, JA Urbina Trends in parasitology 21 (11), 508-512, 2005 | 538 | 2005 |
| Chemotherapy of leishmaniasis SL Croft, V Yardley Current pharmaceutical design 8 (4), 319-342, 2002 | 519 | 2002 |
| Natural products as antiparasitic drugs O Kayser, AF Kiderlen, SL Croft Parasitology research 90, S55-S62, 2003 | 512 | 2003 |
| Leishmaniasis chemotherapy—challenges and opportunities SL Croft, P Olliaro Clinical microbiology and infection 17 (10), 1478-1483, 2011 | 499 | 2011 |
| Leishmaniasis: new approaches to disease control CR Davies, P Kaye, SL Croft, S Sundar Bmj 326 (7385), 377-382, 2003 | 475 | 2003 |
| Bisphosphonates Inhibit the Growth of Trypanosoma b rucei, Trypanosoma c ruzi, Leishmania d onovani, Toxoplasma g ondii, and Plasmodium f alciparum: A Potential Route to … MB Martin, JS Grimley, JC Lewis, HT Heath, BN Bailey, H Kendrick, ... Journal of medicinal chemistry 44 (6), 909-916, 2001 | 426 | 2001 |
| Management of trypanosomiasis and leishmaniasis MP Barrett, SL Croft British medical bulletin 104 (1), 175-196, 2012 | 396 | 2012 |
| Chemotherapy in the treatment and control of leishmaniasis J Alvar, S Croft, P Olliaro Advances in parasitology 61, 223-274, 2006 | 370 | 2006 |
| Structure–activity relationships of antileishmanial and antimalarial chalcones M Liu, P Wilairat, SL Croft, ALC Tan, ML Go Bioorganic & medicinal chemistry 11 (13), 2729-2738, 2003 | 365 | 2003 |
| 2-and 3-substituted 1, 4-naphthoquinone derivatives as subversive substrates of trypanothione reductase and lipoamide dehydrogenase from trypanosoma c ruzi: Synthesis and … L Salmon-Chemin, E Buisine, V Yardley, S Kohler, MA Debreu, V Landry, ... Journal of medicinal chemistry 44 (4), 548-565, 2001 | 355 | 2001 |
| Artemisone—a highly active antimalarial drug of the artemisinin class RK Haynes, B Fugmann, J Stetter, K Rieckmann, HD Heilmann, HW Chan, ... Angewandte Chemie International Edition 45 (13), 2082-2088, 2006 | 316 | 2006 |
| The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani SL Croft, RA Neal, W Pendergast, JH Chan Biochemical pharmacology 36 (16), 2633-2636, 1987 | 313 | 1987 |
| Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH3 (edelfosine) and amphotericin B P Escobar, S Matu, C Marques, SL Croft Acta tropica 81 (2), 151-157, 2002 | 297 | 2002 |
| Formulation of amphotericin B as nanosuspension for oral administration O Kayser, C Olbrich, V Yardley, AF Kiderlen, SL Croft International journal of pharmaceutics 254 (1), 73-75, 2003 | 287 | 2003 |
